Mayo Clinic Gastrointestinal Cancers 2027	
The Ritz-Carlton Ballroom, The Ritz-Carlton, Rancho Mirage, CA	
April 2-3, 2027	
Day 1	**Friday, April 2, 2027**
6:30 AM	**Registration, Breakfast, and Exhibits**
7:30 AM	**Welcome Announcements** Tanios S. Bekaii-Saab, M.D.
Session I: Pancreas and Neuroendocrine Cancers **Moderator: Ben George, M.B.B.S., M.D.**	
7:40 AM	**Radionuclide Therapy in Neuroendocrine Tumors: PRRT Beyond Beta: The Emerging Role of Alpha Emitters** Thorvadur R. Halfdanarson, M.D.
8:10 AM	**RAS Inhibition in Pancreas Cancer: A Seismic Shift in Therapeutic Strategy** Tanios S. Bekaii-Saab, M.D.
8:40 AM	**Beyond RAS Inhibition: Prioritizing Molecular Targets and Trial Strategies in Pancreatic Cancer** Michael J. Pishvaian, M.D., Ph.D.
9:10 AM	**Bringing Precision Therapy Earlier in Pancreatic Cancer: Designing the Right Perioperative Trials** John H. Strickler, M.D.
9:40 AM	**AM Break and Exhibits**
Session II: Hepatocellular Carcinoma **Moderator: Umair Majeed, M.B.B.S., M.D.**	
10:10 AM	**Case Presentations: Can We Get This Patient to Transplant? Cases of HCC Downstaging** **Presenter:** Thomas J. Byrne, M.D. **Panel:** Kris P. Croome, M.D., Anthony B. El-Khoueiry, M.D., and Rory L. Smoot, M.D.
11:00 AM	**Intermediate-Stage HCC: Systemic Therapy Alone or in Combination With Locoregional Therapy?** Anthony B. El-Khoueiry, M.D.
11:30 AM	**Resectable HCC: Is It Time to Rethink the Perioperative Paradigm?** Rory L. Smoot, M.D.
12:00 PM	**Lunch and Exhibits**
12:00 PM	**Optional Product Theater: Company 1 (no CME)**

	Location: The Springs Conference Room
Session III: Biliary Cancers Moderator: Seyi B. Abidoye, M.B.B.S.	
1:00 PM	**FGFR2 Fusion–Positive Cholangiocarcinoma: Are We Ready to Move Targeted Therapy to the Front Line?** Daniel H. Ahn, D.O.
1:20 PM	**Perioperative Management of Biliary Tract Cancer: Current Evidence and Future Directions** TBC
Session IV (part 1): Gastric and Esophageal Cancers Moderator: Jason S. Starr, D.O.	
1:40 PM	**Organ Preservation in dMMR Gastric/Esophageal Cancer** TBC
2:10 PM	**Spatial Architecture in GI Cancers: Why Does it Matter and How Will It Affect Clinical Care?** Kristina A. Matkowskyj, M.D., Ph.D.
2:40 PM	**Break and Exhibits**
Session IV (part 2): Gastric and Esophageal Cancers Moderator: Ryan C. Augustin, M.D.	
3:10 PM	**Targeting HER2 in Esophageal/Gastric Cancer: Beyond Trastuzumab** Raghav Sundar, M.D., Ph.D.
3:35 PM	**Next Generation CLDN18.2 Targeting** Florian Lordick, M.D., Ph.D.
4:05 PM	**Looking Ahead in Gastroesophageal Cancer: Immunotherapy and Emerging Therapies** Nataliya V. Uboha, M.D., Ph.D.
4:30 PM	**Closing Remarks and Adjourn** Harry H. Yoon, M.D.

Day 2	Saturday, April 3, 2027
6:30 AM	**Breakfast and Exhibits**
6:30 AM	**Optional Product Theater: Company 2 (no CME)** **Location: The Springs Conference Room**

7:30 AM	**Welcome Announcements** Tanios S. Bekaii-Saab, M.D.
Session V: TBC **Moderator: Jeremy C. Jones, M.D.**	
7:40 AM	**Case Presentation: Rectal Cancer: More Options, Harder Decisions. Picking the Right Strategy for the Right Patient** **Presenter:** Conor D. O'Donnell, M.B., B.Ch., B.A.O. **Panel:** TBC, John H. Strickler, Justin T. Brady, M.D., Toufic Kachaamy, M.D., Eiji Oki B.E., M.E., Ph.D.
8:40 AM	**Beyond Prognosis: Moving MRD Into Treatment Decision-Making in Colorectal Cancer** Takayuki Yoshino, M.D., Ph.D.
9:10 AM	**Liver Transplantation in CRC: Patient Selection, Timing, and Outcomes** Kris P. Croome, M.D.
9:40 AM	**Break and Exhibits**
Session VI: Advanced Stage Colorectal Cancers **Moderator: Christina S. Wu, M.B., B.Ch., M.D.**	
10:10 AM	**From Molecular Selection to Immune Engagement: Redefining First-Line Therapy in mCRC** Christopher H. Lieu, M.D.
10:40 AM	**Refractory mCRC: How Do We Turn Modest Gains Into Meaningful Benefit?** Bassel F. El-Rayes, M.D.
11:10 AM	**Early-Onset CRC: Defining When Genetics Matters—and When It Does Not** Jewel J. Samadder, M.D.
11:40 AM	**The Next Wave in GI Oncology: New Targets, New Modalities, New Opportunities** Kristen K. Ciombor M.D., M.S.C.I.
12:10 PM	**Closing Remarks and Adjourn** TBC